We sincerely thank all participating institutions for their valuable contribution to the REGYS project, a retrospective study focused on rare gynecological sarcomas, which has so far resulted in five publications — three in Q1 journals and two in Q2 journals.

In addition, at least two further publications, focusing on MTAP deletion and on an mRNA expression profile classifier, are currently in preparation and will also be co-authored by all participating institutions.

Given the uniqueness of the collected samples, we are now preparing a follow-up project: REGYS-2. Details of the new REGYS-2 project will be shared soon, along with an invitation to participate. We sincerely hope for your continued collaboration.

Publications co-authored by all participating institutions:

1.     Dundr P, et al. The Rare Gynecologic Sarcoma Study: Molecular and Clinicopathologic Results of A Project on 379 Uterine Sarcomas. Lab Invest. 2025 May;105(5):104092. doi: 10.1016/j.labinv.2025.104092

2.     Hojný J, et al. Decoding the Molecular Landscape of 262 Uterine Sarcomas: RNA-Seq Clustering of ESS, UTROSCT, and UUS with Prognostic Insights. Lab Invest. 2025 May 24:104198. doi: 10.1016/j.labinv.2025.104198

3.     Flídrová M, et al. Immunohistochemical analysis of 147 cases of low-grade endometrial stromal sarcoma: refining the immunohistochemical profile of LG-ESS on a large, molecularly confirmed series. Virchows Arch. 2025 Jan 21. doi: 10.1007/s00428-025-04026-4

Publications co-authored by contributing institutions only:

1.     Dundr P, et al. Uterine sarcoma with KAT6B/A::KANSL1 fusion: a molecular and clinicopathological study on 9 cases. Virchows Arch. 2025 Mar;486(3):551-562. doi: 10.1007/s00428-024-03994-3

2.     Flídrová M, et al. Unraveling the Molecular Landscape of Uterine Tumor Resembling Ovarian Sex Cord Tumor: Insights From A Clinicopathological, Morphologic, Immunohistochemical, and Molecular Analysis of 35 Cases. Mod Pathol. 2024 Dec;37(12):100611. doi: 10.1016/j.modpat.2024.100611

We look forward to continuing this important collaboration in the upcoming REGYS-2 project.

The State-of-the-Art Conference on Gynecology and Oncology is fast approaching! As a reminder, the conference will take place on September 29–30, 2025, in Prague.

If you have not registered yet, please do so as soon as possible at www.sago-conference.eu.

We look forward to seeing you in Prague, catching up in person, and sharing an inspiring programme together!

The CEEGOG representatives for the upcoming GCIG 7th Ovarian Cancer Consensus Conference – Clinical Research, to be held on April 30 – May 1, 2026, in Toronto, Canada, have been selected recently.

Following a thorough review by the CEEGOG Scientific Committee, the following physicians have been chosen as our nominees:

David Cibula – Gynaecological Oncology

Filip Frühauf – Diagnostics, Gynaecological Oncology

Lika Katselashvili – Medical Oncology

Marija Živković Radojević – Radiation Oncology

In line with GCIG guidelines, each GCIG group may nominate up to four delegates, from which the OCCC-CR Executive Committee will select two final participants to ensure balanced representation of disciplines across all topic groups.

We sincerely thank all applicants for their interest in representing CEEGOG and for their ongoing commitment to advancing collaborative international research in gynaecologic oncology.

Final outcome paper of the SENTIX study published in Nature Cancer!

We are pleased to share the latest publication from the ENGOT-Cx2/CEEGOG CX-01/SENTIX academic surgical trial, now published in Nature Cancer.

This prospective, single-arm, international trial evaluated the safety of sentinel lymph node biopsy without systematic pelvic lymphadenectomy in patients with early-stage cervical cancer. The final survival outcomes provide valuable evidence to inform both clinical practice and future research.

Notably, half of the patients enrolled in the SENTIX study came from CEEGOG sites. We sincerely thank all participating sites and collaborators for their invaluable contribution.

📄 Read the full article here: https://www.nature.com/articles/s43018-025-01016-y#citeas

We are pleased to announce that the final results of the CEEGOG EX-02 / TESLA-1 study have been published in the journal Cancers.

TESLA-1 was a prospective observational study in patients with early-stage endometrial cancer, comparing two concurrent sentinel lymph node (SLN) labelling techniques: a radioactive tracer (with or without blue dye) versus indocyanine green (ICG). The primary objective was to evaluate and compare the SLN detection rate between these two intracervical tracer methods.

We sincerely thank all participating sites for their valuable cooperation. It was a great pleasure to work with you on this study!

📄 Read the full article here: https://www.mdpi.com/2072-6694/17/10/1606

The 2025 GCIG Spring Meeting in Chicago gathered over 170 delegates from all 33 member groups, focusing on pragmatic trials – cost-effective, patient-centred studies applicable in real-world clinical practice, including low-resource settings. The meeting featured impactful plenary sessions, pre-recorded lectures, and interactive brainstorming in disease-specific groups. Discussions covered topics such as:

  • Involving patients from trial design to result dissemination
  • Reducing toxicity without compromising efficacy
  • Innovative approaches like synthetic control arms, dose de-escalation, fertility-sparing approaches, AI modelling, and decentralized trials
  • Designing inclusive protocols with broader eligibility criteria
  • New proposals in ovarian, endometrial, cervical, and rare tumours, as well as symptom benefit research

 

The brainstorming sessions generated 33 trial concepts, of which 15 were discussed in detail. Early Career Investigators played an active role, contributing ideas and collaborating internationally.

CEEGOG was represented by Dr. Zoltán Novák from the National Cancer Institute, Budapest. Our sincere thanks to Dr. Novák for representing our group at this important international meeting.

The next GCIG Autumn Meeting will be held on October 15–16, 2025, in Berlin, Germany.

On May 23, 2025, the annual CEEGOG meeting took place in Prague, bringing together 67 participants representing 41 sites. We thank all who joined and contributed to the discussions.

Key highlights from the meeting:

  • Awards to the 10 most active sites in academic research in 2024 (certificates + ESGO 2026 registration fee covered by CEEGOG).
  • 4 academic trials open for collaboration: MYSTR, CERVANTES, RECER, RACE.
  • Achievements in 2024 & 2025 include initiation of academic and commercial ENGOT studies in multiple CEEGOG countries, SENTIX final outcome accepted for publication in Nature Cancer and CEEGOG joining ENGOT Leadership for 2026–2028.
  • New proposals: 3 prospective studies and 1 survey.
  • Reminder: according to updated CEEGOG Bylaws, sites without research activity will be excluded from the CEEGOG Board.

We thank all CEEGOG members for their continued support and collaboration on CEEGOG/ENGOT/GCIG projects and wish everyone a relaxing and enjoyable summer!

 

Photo Gallery – CEEGOG Annual Meeting 2025
A few moments captured from our annual meeting in Prague. Thank you to everyone who joined and contributed to the success of this year’s event.

 

 

New Publication from CEEGOG CX-07 / RECER Study

We are pleased to announce the publication of a new article related to the CEEGOG CX-07/RECER study in the International Journal of Gynecological Cancer.

The RECER study aims to evaluate the risk factors associated with the regression or persistence of high-grade cervical lesions (HG lesions).

We also remind our members and collaborators that there is still an opportunity to participate in this ongoing academic CEEGOG study. If you are interested in joining or would like to receive more information, please feel free to contact the CEEGOG office.

We sincerely thank all participating sites for their continued support and collaboration.

📄 Read the article here: https://www.international-journal-of-gynecological-cancer.com/article/S1048-891X(25)00885-0/fulltext

The latest ENGOT meeting, held on April 3-4, 2025, gathered representatives from all ENGOT groups to review progress across numerous ongoing and completed trials, present updates from working groups, and discuss strategic priorities.

CEEGOG was represented by its Chair Prof. David Cibula and Administrative Manager Mrs. Ivana Nohová. From the CEEGOG studies, updates on the SENTIX and CERVANTES were presented.

Highlights included:

  • Clinical Trials – Updates on recruitment, regulatory progress, and key milestones across multiple ENGOT model A, B, and C studies in ovarian, endometrial, and cervical cancer s well as an overview of new proposals, including all GCA 2024 trial proposals.
  • Scientific Achievements – Several trials are nearing completion, with data expected to be presented at major conferences such as ESGO, ESMO, and ASCO in 2025–2026.
  • Working Group Reports – Operational updates, improved templates for contracts and trial budgeting, and new guidelines for ENGOT presentations to pharmaceutical companies.
  • Strategic Discussions – Strengthening academic trial support, refining publication rules, ensuring representation in trial steering committees, and planning for future leadership rotations.
  • Collaborative Initiatives – Expansion of the Rare Tumour Registry, TR group biobank projects, and ESGO database.

CEEGOG is now a full partner in most clinical trials which influence the standard of care. We thank all participating sites for their interest in offering new treatment options to their patients and for their commitment to clinical research as a whole.

We are pleased to invite you to the State-of-the-Art Conference on Gynecology and Oncology, a brand-new type of meeting organized by the Central and Eastern European Gynecologic Oncology Group (CEEGOG). The conference will take place on September 29–30, 2025, in Prague, and will offer not only an excellent educational programme but also a unique opportunity to showcase the dynamic Central and Eastern European region.

The conference will provide a comprehensive overview of the latest recommendations across the entire field – from diagnosis and surgical treatment to systemic therapies and palliative care. Most of the speakers will come from our region east of the German border, offering valuable regional insights.

More information is available on the conference website: www.sago-conference.eu

We look forward to welcoming you all to Prague in September 2025! 

 

We are pleased to invite you to  the next year’s Annual Meeting of our Collaborative Group CEEGOG, which will take place on Friday, May 23, 2025, at the Department of Gynecology, Obstetrics, and Neonatology of the General University Hospital in Prague.

We look forward to the opportunity to meet you all in Prague and kindly ask you to save the date of 23 May 2025. Thank you in advance.

 

  1. GCIG Fall meeting, November 18 and 21, and December 6, 2024
  2. ENGOT GCA workshop, Stresa, Italy, November 13 – 15, 2024
  3. Annual CEEGOG mtg in Prague scheduled for MAY, 2025
  4. CEEGOG OX-01/HE4-FU-OVCA - article published
  5. GCIG CCCC CR, Dublin, Ireland, October 14 - 15, 2024
  6. ENGOT meeting in Amsterdam, September 26 – 27, 2024
  7. New CEEGOG leadership and members of the CEEGOG Scientific committee, JUNE 2024
  8. Annual CEEGOG mtg in Prague on JUNE 14-15, 2024
  9. CEEGOG meeting in BARCELONA at ESGO congress 2024
  10. Separation of Polish centers from the CEEGOG group